darexaban
Small moleculeexperimental
Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011. — Wikipedia
Clinical trial activity
25 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
10
Phase 3
7
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT01514812)
Timeline
Indications
Mechanism of action
- Coagulation factor XINHIBITOR
F10 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1- Mol. weight
- 474.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDarexaban ↗
- ChEMBLCHEMBL1922235 ↗
Also known as
- darexaban
- darexaban
- darexaban
- darexaban
- darexaban maleate
- n-(2-hydroxy-6-(4-methoxybenzamido)phenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide
- ym150
- ym150
- ym 150
- ym-150
- ym150 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01125657 | Phase 1 | Feb 1, 2010 | Astellas |
| NCT01125670 | Phase 1 | Feb 1, 2010 | Astellas |
| NCT01409603 | Phase 1 | Jan 1, 2010 | Astellas, SGS Life Sciences |
| NCT01405989 | Phase 1 | Jan 1, 2010 | Astellas, SGS Life Sciences |
| NCT01406002 | Phase 1 | Jan 1, 2010 | Astellas, SGS Life Sciences |
| NCT01118559 | Phase 1 | Nov 1, 2009 | Astellas |
| NCT00994292 | Phase 2 | Sep 1, 2009 | Astellas |
| NCT00938730 | Phase 2 | Jun 1, 2009 | Astellas |
| NCT00937820 | Phase 3 | Jun 1, 2009 | Astellas |
| NCT00937911 | Phase 3 | Jun 1, 2009 | Astellas |
| NCT00942435 | Phase 3 | Jun 1, 2009 | Astellas |
| NCT00913120 | Phase 2/Phase 3 (Phase 3) | May 1, 2009 | Astellas |
| NCT01028950 | Phase 3 | May 1, 2009 | Astellas |
| NCT00917254 | Phase 2/Phase 3 (Phase 3) | May 1, 2009 | Astellas |
| NCT01409616 | Phase 1 | Apr 1, 2009 | Astellas, SGS Life Sciences |
| NCT00902928 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2009 | Astellas |
| NCT00595426 | Phase 2 | May 1, 2008 | Astellas |
| NCT01424332 | Phase 1 | Dec 1, 2007 | Astellas, SGS Life Sciences |
| NCT00448214 | Phase 2 | Mar 1, 2007 | Astellas |
| NCT01657981 | Phase 1 | Feb 1, 2007 | Astellas |
Showing 20 of 25 trials
Page 1 / 2
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 25 | 25 | 3 | 2006 |
| SGS Life Sciences | For profit | 5 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1